PowerShares Dynamic Biotech &Genome ETFFund
- Change -0.11 (-0.2%)
- Volume 0.03 M
4:00 PM EDT May 21, 2015
U.S. Markets are closed
- Assets $556.7M
- Expense Ratio 0.63%
- Yield N/A
- Vs 50 Day EMA %
- Vs 200 Day EMA %
US Equity ETF
PowerShares Dynamic Biotechnology & Genome Portfolio is an exchange-traded fund incorporated in the USA. The Fund seeks investment results that correspond to the price and yield of the Dynamic Biotechnology & Genome Intellidex Index a fundamentally-weighted index. Securities shown to possess the greatest capital appreciation potential are selected by the Index.
|TODAY||1 DAY||5 DAY||10 DAY||1 MO||3 MO||6 MO||1 YR||2 YR||5 YR|
Last Close Volume
|AVG VOL (10 D)||CHANGE|
Trend on Last Close
|Price||EMA||EMA P||DATE CROSSED|
04-01-2015 07:45 AM by Todd Shriber
Shares of Dyax Corp. (NasdaqGS: DYAX) surged nearly 50% during Tuesday's after-hours session after the Massachusetts-based company said an early stage trial of its treatment for hereditary angioedema proved safe for use and effective in reducing extreme swelling attacks. Dyax ...
03-10-2015 11:00 AM by Todd Shriber
On the heels of last week's news that AbbVie (NYSE: ABBV) will acquire cancer treatments maker Pharmacyclics (NasdaqGS: PCYC) for $21 billion, speculation is abound regarding the next potential takeover targets in the biotechnology industry. The biotech industry and the releva...
03-05-2015 07:30 AM by Todd Shriber
Shares of Pharmacyclics (NasdaqGS: PCYC), a maker of cancer treatments, rose more than 2% during Wednesday's after-hours session following a 6.3% surge on almost two and a half times the average voile during tradition trading hours on reports Dow component Johnson & Johnson (...
01-05-2015 08:00 AM by Todd Shriber
Over the last several years, there has rarely been a bad time to own biotechnology exchange traded funds. That much is confirmed by the presence of multiple biotech ETFs on the annual lists of the top 10 sector funds. In 2014, each of the five major biotech ETFs ranked among t...
11-20-2014 09:30 AM by Todd Shriber
Stellar performances by health care stocks and exchange traded funds this year have been well-document and plenty of investors know that the Health Care Select Sector SPDR (NYSEArca: XLV) is the best of the nine sector SPDR ETFs to this point in the year. Up 24.7% year-to-date...
10-23-2014 11:49 AM by Todd Shriber
U.S. stocks appear headed for a fifth consecutive day of gains. While that is good news, the S&P 500's recent winning streak serves as a reminder regarding why October is, historically, the most volatile month of the year. Despite that volatility, biotechnology exchange tr...
10-15-2014 08:00 AM by Tom Lydon
One of this year's sharpest pullbacks in equities was, some market observers would say, attributable to the late first-quarter/early second-quarter retrenchment in biotechnology stocks and the corresponding exchange traded funds. So severe was the aforementioned selloff in bio...
09-03-2014 11:00 AM by Tom Lydon
It was a frequent event in the month of August. Throughout the month, daily checks of exchange traded funds making new all-time highs turned up plenty of health care funds. Much to the chagrin of the biotechnology bears that growled so loud late in the first quarter and early ...
08-25-2014 09:00 AM by Tom Lydon
Monday could prove to be another day of biotechnology merger mania for the exchange traded funds holding the sector's stocks after Swiss pharmaceuticals giant Roche announced Sunday it will acquire InterMune (NasdaqGS: ITMN) for $8.3 billion in cash. Roche will pay $74 per sha...
08-20-2014 12:28 PM by Todd Shriber
It seems like only yesterday that there was a cacophony of criticism and doubt from naysayers regarding biotechnology stock and exchange traded funds. In reality, "yesterday" was the first quarter when the usually pricey biotech sector soared to valuations that were double its...
06-14-2014 08:00 AM by Todd Shriber
U.S. stocks managed to closer higher Friday, but in a case of June gloom, the S&P 500 snapped a multi-week winning streak. Escalating tensions at the hands of a militant faction of al-Qaeda in Iraq weighed on stocks, but sent oil prices soaring. On that note, it is surpris...
06-09-2014 01:25 PM by Todd Shriber
Perhaps it is just the way the media operate, an unfortunate byproduct of people paying ample attention to negative news or both, but there is a rally going on in biotechnology stocks and exchange traded funds that is receiving scant attention. From its March 4th peak to its A...
06-09-2014 12:09 PM by Tom Lydon
The PowerShares Dynamic Biotechnology & Genome Portfolio (NYSEArca: PBE) and the SPDR S&P Biotech ETF (NYSEArca: XBI) are up 8.4% and 6.8%, respectively, Monday, making the duo the day's two best non-leveraged ETFs. PBE and XBI are soaring because the two ETFs feature ...
05-06-2014 12:46 PM by Todd Shriber
From its Feb. 25 to its April 14 lows, the iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB) tumbled 21.2%. That fits the definition of a bear market and IBB's decline, along those of the other biotech ETFs, received ample attention due in large part to talk that the biotech se...
04-10-2014 02:16 PM by Todd Shriber
More bad price action out of the biotechnology sector Thursday and that underscores the precarious technical conditions being faced some exchange traded funds that were beloved just several weeks ago. Here is a brief recap of just how bad biotech stocks and ETFs have been sinc...
04-08-2014 12:45 PM by Todd Shriber
It has been said, and it is more often than not true, that flows data for exchange data is not a predictor of future performance, but rather a sign of investors chasing past performance. When it comes to once beloved biotechnology ETFs, it is not debatable that the group's rec...
03-26-2014 08:15 AM by Tom Lydon
The subject has been talked to death over the past week, but that does not mean attention on the biotech sector is waning. Amid increased talk of a biotech bubble and fears of government-controlled pricing, biotech stocks and exchange traded funds have been under siege in rece...
03-06-2014 11:54 AM by Todd Shriber
On the surface, it would appear that equity-based exchange traded funds are struggling to keep and attract assets this year. Inflows to equity ETFs do not look poised to recapture last year's magic. Even when backing out the $17.4 billion lost by the SPDR S&P 500 (NYSEArca...
02-21-2014 08:15 AM by Todd Shriber
There are five biotechnology exchange traded funds on the market today. Confirming just how strong the sub-sector has been this year three of those ETFs – the First Trust NYSE Arca Biotechnology Index Fund (NYSEArca: FBT), the Market Vectors Biotech (NYSEArca: BBH) and the iShare...
02-14-2014 08:00 AM by Todd Shriber
Forty-seven exchange traded funds hit all-time highs on Thursday. In a testament to the ongoing strength of the health care sector, now the third-largest in the S&P 500, 16 of the ETF's touching all-time highs yesterday were health care funds. This is not a new phenomenon....
01-09-2014 01:57 PM by Todd Shriber
No need to do a double take with the following because it is true: Shares of Intercept Pharmaceuticals (NasdaqGM: ICPT) are up $210, or a tidy 290%, after trials for the company's liver disease treatment proved successful. That is good news for the biotechnology sector, which ...
12-23-2013 08:00 AM by Tom Lydon
This has been, quite simply a very, very good year in which to be long health care exchange traded funds. The Health Care Select Sector SPDR (NYSEArca: XLV) is battling with its discretionary rival to be the best of the nine SPDR ETFs for 2013 and XLV spent some time as the th...
10-31-2013 02:45 PM by Max Chen
Biotech exchange traded funds, market leaders for much of this year, stumbled in October as the government shutdown had an unexpectedly debilitating affect on the high-flying sub-industry. The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), which tracks large biotech or phar...
10-10-2013 07:30 AM by Tom Lydon
Biotechnology exchange traded funds are on a three-day sell-off after falling short of its 52-week high Friday, but the sector can still find its footing. The he iShares Nasdaq Biotech (NasdaqGM: IBB) has declined 7.5% in the past three sessions, Market Vectors Biotech ETF (NY...
10-08-2013 01:14 PM by Tom Lydon
Riding out tax hikes, interest rate risk and geopolitical tensions, the broad equity markets touched historic highs this year, with alternative energy, biotech and technology stock exchange traded funds leading the pack. In the technology space, social media stocks are experie...
09-03-2013 04:10 PM by Tom Lydon
Rummaging through small-cap biotechnology companies, investors can pick out the next break-through drug provider, but it also leaves you exposed to potential flubs. Instead, exchange traded funds offer diversified basket to the growing sector. "The jarring pace of change, sing...
08-19-2013 04:39 PM by Tom Lydon
The biotechnology sector has been one of the best performing areas in the market this year. While investors can try to bet big, and potentially lose big, on biotech stocks, an exchange traded fund helps diversify risk with a basket of securities. "The jarring pace of change, s...
04-20-2012 03:09 PM by Tom Lydon
Coming off the hopeful drug trial tests and lucrative takeover bids, the biotech sector and related exchange traded funds that follow the industry surged this week. However, some biotechnology ETFs are doing better than the others. The large biotech firms are flush with cash a...
06-13-2011 01:53 PM by Tom Lydon
Biotechnology exchange traded funds were mixed Monday after sector bellwether Gilead Sciences (NasdaqGS: GILD) disclosed it has received a subpoena from the U.S. Department of Justice. Gilead shares were down nearly 1% but pared their earlier loss after the company late Friday...
02-22-2011 02:00 PM by Tom Lydon
While the broader market has picked up its pace, the biotechnology sector has not seen a similar surge in performance. Still, investors should keep in mind the various biotech exchange traded fund (ETF) plays to stay positioned for a resurgence in the sector. Currently, the bi...
11-10-2010 11:00 AM by Tom Lydon
After the Democrats lost some seats in the mid-term elections, you might be wondering whether health care revenue and exchange traded funds (ETFs) will be affected by the shift. Some don't believe there's anything to worry about for a while. First, with most corporations backi...
10-21-2010 03:00 PM by Tom Lydon
The biotechnology sector is a unique one because many of the companies that compose it are not yet profitable. Here's what drives the sector and exchange traded funds (ETFs) that let you play it. Kashif Javed for Forex Trading Analysis reports that the biotech sector is driven...
10-11-2010 06:00 AM by Tom Lydon
As cash-strapped biotech companies see their cash reserves dwindle, it has forced a number of companies to close up shop. The struggles faced in the sector highlights the benefits of getting exposure to it through biotech exchange traded funds (ETFs). The number of publicly-t...
08-08-2010 01:00 PM by Tom Lydon
Biotechnology has been improving our quality of life for generations. The industry does everything from researching a cure for cancer to finding disease-resistant crops and more. While this can be a difficult sector in which to invest, there are five exchange traded funds (ETFs) ...
06-25-2010 01:00 AM by Tom Lydon
Biotechnology has helped improve the lives of many people. Naturally, many biotech stocks boom or bust based on the success of products in their pipeline. But if you're looking for a more diversified and steady approach to biotech investing, look no further than exchange traded f...
02-05-2010 02:00 PM by Tom Lydon
Biotechnology is continuously advancing and the future may lie in personalized medicine. The biotech sector, along with related exchange traded funds (ETFs), may see billions in revenue as this market grows in the coming years. Biotech companies, investors, providers and big p...
11-19-2009 02:00 PM by Tom Lydon
The biotechnology sector is once again finding its footing, with some exchange traded funds (ETFs) focused on the sector up more than 30% since the market's March 9 low. But there have been stumbling blocks on the way back to profitability. A reputable biotechnology company h...
09-04-2009 02:00 PM by Tom Lydon
The biotechnology sector and its related exchange traded funds (ETFs) have seen a handsome rebound off the March 9 lows, but does the cash-strapped sector have what it takes to survive for the long haul? Analysts estimate that nearly half of all biotechnology firms have insuf...
08-06-2009 01:00 AM by Tom Lydon
The biotechnology sector and exchange traded funds (ETFs) have had a good summer so far. Some funds are up as much as 22% in the last month alone. Will it continue? July was kind to the biotech sector. The NYSE Biotechnology Sector rose up 24%, which dwarfed the 6% for the S&a...
07-29-2009 02:00 PM by Tom Lydon
ETF Spotlight on PowerShares Dynamic Biotech & Genome (PBE), part of a weekly series. Assets: $148 million Holdings: This fund invests in companies involved in the biotechnology and genome sectors. Some of the top components include ImmunoGen (IMGN), Amgen (AMGN), Gilead S...
07-08-2009 12:00 PM by Tom Lydon
A small piece of the 2009 Economic Stimulus Package will revamp aid to small businesses, which could give way to successful relationships between small pharmaceutical/biotech companies and academic institutions. This may be what related investments and exchange traded funds (ET...
06-27-2009 01:00 AM by Tom Lydon
In an attempt to reduce costs in the health care industry, the government will be legislating for cheaper drugs, but drug makers, along with related exchange traded funds (ETFs), may see profits slip away. The Obama administration claims that biologic drugs should be subject t...
06-17-2009 11:00 AM by Tom Lydon
Biotechnology stocks present opportunities, but given the unique challenges of the sector, exchange traded funds (ETFs) may be the better route to go if you're considering making an investment. Owning individual biotechnology companies can be a challenging way to invest in th...
06-15-2009 12:00 PM by Tom Lydon
Biotechnology and health care-related exchange traded funds (ETFs) could be set to take off as both sectors are in a transition period and are gaining more support from the Obama administration. President Barack Obama today met with the American Medical Association about his...
02-19-2009 06:00 AM by Tom Lydon
When President Barack Obama put his John Hancock on the $787 billion stimulus package, $140 billion of it was related specifically to fixing health care and, in turn, related exchange traded funds (ETFs). What's in the bill? A provision to help workers who lose their j...
09-18-2008 12:00 PM by Tom Lydon
The PowerShares exchange traded fund (ETF) family is adding a slew of new members this week. The PowerShares Global Biotech Portfolio (PBTQ) covers the growth of this industry. The biotech industry has seen increasing growth and revenue base over the past two years. No single ...
08-14-2008 01:00 PM by Tom Lydon
Biotechnology stocks and exchange traded funds (ETFs) could get a shot in the arm, as Genentech (DNA) rejected a takeover bid from Roche, which they feel has undervalued the company. Roche, the Swiss pharmaceutical company, offered Genentech an initial bid of $43.7 billion, wh...
07-27-2008 01:00 AM by Tom Lydon
Biotechnology appeals to many investors, and with four different exchange traded funds (ETFs) focused on the class, is there a fund that is better than the rest? The sector is one of the few non-commodity related that's solidly above its trend line. Each of the four ETFs wi...
07-16-2008 11:00 AM by Tom Lydon
Biotechnology is the non-commodity exchange traded fund (ETF) area du jour, it seems. In a time where the markets seem bleak, the sector is delivering a ray of light. Genentech (DNA) this week upped its 2008 forecast, and also said its second-quarter profit rose 4.7%, thanks t...
Number of Holdings: 30
|Life Sciences Tools & Services||5.9%|
|Scientific Instruments: Control & Filter||2.7%|
|Life Science Equipment||21.8%|
|Health Care Supplies||2.7%|
Number of Holdings: 30
|5.8%||REGN||Regeneron Pharmaceut...||Technology||48660220000||United States|
|5.7%||PCYC||Pharmacyclics Inc||Technology||19347060000||United States|
|5.6%||BMRN||BioMarin Pharmaceuti...||Technology||18582990000||United States|
|5.1%||VRTX||Vertex Pharmaceutica...||Technology||30597830000||United States|
|5.1%||GILD||Gilead Sciences Inc||Technology||155736410000||United States|
|4.9%||AMGN||Amgen Inc||Technology||121925500000||United States|
|4.6%||BIIB||Biogen Inc||Technology||90850620000||United States|
|4.6%||DYAX||Dyax Corp||Technology||3635290000||United States|
|4.3%||ALXN||Alexion Pharmaceutic...||Technology||34426990000||United States|
|4.2%||RGEN||Repligen Corp||Technology||1034490000||United States|
Members see all holdings. Not a member yet? Click here to join.